AstraZeneca, the pharmaceuticals major, has projected that its revenue and core earnings per share will grow by double-digit percentages in 2024. The company recently reported its fourth-quarter results, which showed…
Shares of AstraZeneca saw a significant increase in early trade, rising as much as 4.2%, following the company's announcement that it has raised its full-year guidance for core earnings per…
The U.S plans to share about 60 millions doses of AstraZeneca vaccine with the rest of the world according to The Wall Street Journal. Officials also explore an urgent need…
The U.K’s vaccines advisory body has ruled that AstraZeneca’s Covid-19 vaccine should preferably not be given to people under 30 years, according to the Wall Street Journal. The advisory follows…
U.S Data Safety Monitoring Board has expressed concern that AstraZeneca may have included outdated information in trial results of its Covid-19 vaccine, according to CNBC. The concerns cast doubts over…
AstraZeneca and the University of Oxford, the front runners in the delivery of the COVDI-19 vaccine, are facing mounting questions after acknowledging a manufacturing error in their trial results, according…
Traders are worried that complacency over the coronavirus vaccine could affect markets, according to CNBC. Five vaccines, from Moderna, AstraZeneca, Pfizer, Johnson & Johnson, and Novavax are in phase 3…